PubRank

Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia

Clinical Trial ID NCT00005603

PubWeight™ 32.70‹?›

🔗 Visit the ClinicalTrials.gov page for NCT00005603

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia and its relationship to other prognostic factors: a Children's Oncology Group study. Blood 2008 5.49
2 Improved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group. J Clin Oncol 2012 5.08
3 Identification of novel cluster groups in pediatric high-risk B-precursor acute lymphoblastic leukemia with gene expression profiling: correlation with genome-wide DNA copy number alterations, clinical characteristics, and outcome. Blood 2010 4.00
4 Rearrangement of CRLF2 is associated with mutation of JAK kinases, alteration of IKZF1, Hispanic/Latino ethnicity, and a poor outcome in pediatric B-progenitor acute lymphoblastic leukemia. Blood 2010 3.66
5 Absolute lymphocyte counts refine minimal residual disease-based risk stratification in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2011 3.13
6 Gene expression classifiers for relapse-free survival and minimal residual disease improve risk classification and outcome prediction in pediatric B-precursor acute lymphoblastic leukemia. Blood 2009 2.86
7 Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia. JAMA 2009 2.72
8 Relapse-specific mutations in NT5C2 in childhood acute lymphoblastic leukemia. Nat Genet 2013 2.38
9 Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study. Blood 2012 2.09
10 Genome-wide association study identifies germline polymorphisms associated with relapse of childhood acute lymphoblastic leukemia. Blood 2012 1.90
11 Pharmacogenetics of minimal residual disease response in children with B-precursor acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood 2008 1.05
12 A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. Blood 2014 1.04
13 HLA-DRB1*07:01 is associated with a higher risk of asparaginase allergies. Blood 2014 0.94
14 Genome-wide analysis links NFATC2 with asparaginase hypersensitivity. Blood 2015 0.87
15 Clinical and Genetic Risk Factors for Acute Pancreatitis in Patients With Acute Lymphoblastic Leukemia. J Clin Oncol 2016 0.79
Next 100